Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial

(MedPage Today) — SAN FRANCISCO — Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from the phase III PREVAIL…

Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118297

Author :

Publish date : 2025-11-03 22:43:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial

Medicare Finalizes Physician Fee Schedule for 2026

Calls for legal right to paid leave for IVF treatment

Related Posts

A simple hack to help you switch off after work

Ultraprocessed Foods Tied to Early Colorectal Adenoma Risk

Livers of MASLD Patients End Up Less Fatty With Novel Injectable

U.S. Bishops Officially Ban Gender-Affirming Care at Catholic Hospitals

This Drug Might Make Chronic Steroid Therapy Safe in Rheumatic Disease

Managing Hypothyroidism in Older Adults: A Nuanced Decision

A simple hack to help you switch off after work

Ultraprocessed Foods Tied to Early Colorectal Adenoma Risk

Livers of MASLD Patients End Up Less Fatty With Novel Injectable

U.S. Bishops Officially Ban Gender-Affirming Care at Catholic Hospitals

This Drug Might Make Chronic Steroid Therapy Safe in Rheumatic Disease

Managing Hypothyroidism in Older Adults: A Nuanced Decision

Physicians, Hospitals Grapple With Looming Medicaid Cuts

Ancient silver goblet preserves oldest known image of cosmic creation

Categories

Archives